Alzheimer's Club

Hasbrouck Heights, N.J. (19 December 2005) - Nymox (NASDAQ: NYMX) Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

There are a number of ways by which statin therapy may reduce patients' risk of Alzheimer's disease (AD) according to Dr. Steven DeKosky, an AD expert at the Alzheimer Disease Research Center, University of Pittsburgh Medical Center Health System, in a new review article published in a special supplement of The American Journal of Medicine (Statin Therapy: Clinical Trials, Guidelines, and New Directions, December, 2005; 118: 48S-53S). According to Dr. DeKosky, in addition to lowering cholesterol levels, statins may also help suppress production of an amyloid protein believed to play a role in the AD disease process, improve bloodflow function and reduce inflammation, each of which may positively impact on AD risk. The American Journal of Medicine is the official journal of The Association of Professors of Medicine and has the eighth highest scientific impact rating in the world among all general medical journals.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer's disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone.

The potential use of statins to treat Alzheimer's disease (AD) has been widely reported in the peer-reviewed medical literature, both in terms of clinical data, (such as J Neurol Neurosurg Psychiatry (2005; 76:1624-1629); The Lancet Neurology (2005; 4:521-2); Arch Neurol (2005; 62:1047-51); Neurology (2005; 64:1531-8); Arch Neurol (2005; 62:753-7); J Neurol Sci (2005; 229-230:147-50); Curr Opin Lipid (2005; 16:619-623); Arch Gen Psychiatry (2005; 62:217-24)) and possible mechanisms through which statins may prevent or slow the progression of Alzheimer's disease (such as J Neurosci Res (2005; 82:10-19); J Biol Chem (2005; M505268200); PLoS Med (2005; 2:e18); J Neurosci (2005; 25:299-307)).

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

For more info on Statins and Alzheimer's see major subject journal Neurobiology of Lipids, ISSN 1683-5506)

Source: Statin Drugs May Help Reduce Alzheimer's Disease Risk in Many Ways, According to Expert. CCNMatthews (19 Dec 2005) [FullText]